Xu, H.; Sun, Y.; Huang, C.-P.; You, B.; Ye, D.; Chang, C.
Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. Cancers 2020, 12, 831.
https://doi.org/10.3390/cancers12040831
AMA Style
Xu H, Sun Y, Huang C-P, You B, Ye D, Chang C.
Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. Cancers. 2020; 12(4):831.
https://doi.org/10.3390/cancers12040831
Chicago/Turabian Style
Xu, Hua, Yin Sun, Chi-Ping Huang, Bosen You, Dingwei Ye, and Chawnshang Chang.
2020. "Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation" Cancers 12, no. 4: 831.
https://doi.org/10.3390/cancers12040831
APA Style
Xu, H., Sun, Y., Huang, C.-P., You, B., Ye, D., & Chang, C.
(2020). Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. Cancers, 12(4), 831.
https://doi.org/10.3390/cancers12040831